Market Place
Sourcing Support
All News #Library
Biotech
Sanofi, Incyte, Roivant, Alumis Advance In Skin Disease Research
31 Mar 2026 //
BIOSPACE
Alumis Unveils Phase 3 Envudeucitinib Psoriasis Data at 2026
18 Mar 2026 //
GLOBENEWSWIRE
Alumis To Present At Global Healthcare Conference
02 Mar 2026 //
GLOBENEWSWIRE
Alumis To Participate In Upcoming February Investor Conferences
05 Feb 2026 //
GLOBENEWSWIRE
Alumis Closes Upsized Offering as Underwriters Exercise Full
09 Jan 2026 //
GLOBENEWSWIRE
Alumis Announces Phase 3 Breakthrough In Oral Psoriasis Therapy
08 Jan 2026 //
INDPHARMAPOST
Alumis` Envudeucitinib Hits Phase 3 Skin Clearance Goal
06 Jan 2026 //
GLOBENEWSWIRE
Alumis Announces Proposed Public Offering Of Common Stock
06 Jan 2026 //
GLOBENEWSWIRE
Alumis Reveals Q2 2025 Financial Results and Corporate Update
13 Aug 2025 //
GLOBENEWSWIRE
Alumis Completes LUMUS Phase 2b Trial Enrollment for ESK-001
24 Jul 2025 //
GLOBENEWSWIRE
Alumis Completes Ph 3 Enrollment for Oral TYK2 Drug ESK-001
29 May 2025 //
GLOBENEWSWIRE
Alumis and Kaken Pharma Collaborate on ESK-001 in Japan
25 Mar 2025 //
GLOBENEWSWIRE
ESK-001 Ph2 OLE Data Shows 52-Week Psoriasis Response At AAD
08 Mar 2025 //
GLOBENEWSWIRE
Alumis Presents ESK-001’s Potential for Systemic Lupus
14 Nov 2024 //
GLOBENEWSWIRE
Alumis Presents Positive Data from Phase 2 Clinical Trial of ESK-001
09 Mar 2024 //
GLOBENEWSWIRE
Alumis raises $259M in 2024`s largest biotech round so far
06 Mar 2024 //
FIERCE BIOTECH
Alumis Announces Late-Breaker Psoriasis Phase 2 Data Presentation for ESK-001
04 Mar 2024 //
GLOBENEWSWIRE
Alumis Announces Expansion of Allosteric TYK2 Inhibitor, ESK-001, Ph2 Program
29 Jun 2023 //
GLOBENEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.